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Summary
Obesity and type 2 diabetes are strongly associated with abnormal lipid metabolism and accumulation of intramyocellular
triacylglycerol, but the underlying cause of these perturbations are yet unknown. Herein, we show that the lipogenic
gene, stearoyl-CoA desaturase 1 (SCD1), is robustly up-regulated in skeletal muscle from extremely obese humans. High
expression and activity of SCD1, an enzyme that catalyzes the synthesis of monounsaturated fatty acids, corresponded
with low rates of fatty acid oxidation, increased triacylglycerol synthesis and increased monounsaturation of muscle lipids.
Elevated SCD1 expression and abnormal lipid partitioning were retained in primary skeletal myocytes derived from obese
compared to lean donors, implying that these traits might be driven by epigenetic and/or heritable mechanisms. Overex-
pression of human SCD1 in myotubes from lean subjects was sufficient to mimic the obese phenotype. These results
suggest that elevated expression of SCD1 in skeletal muscle contributes to abnormal lipid metabolism and progression
of obesity.Introduction
Obesity and type 2 diabetes are two closely connected meta-
bolic diseases that are now invading Westernized societies at
epidemic rates. The onset of insulin resistance, a hallmark
pathophysiological feature of type 2 diabetes, usually occurs
after a period of weight gain. The temporal relationship be-
tween these two diseases implies that increased adiposity and/
or a high lipid environment somehow decay insulin’s ability to
regulate glucose homeostasis. A unifying theme that has
emerged during the past decade suggests that lipid oversupply
to metabolic organs responsible for glucose regulation, such
as muscle, liver, and pancreas, eventually leads to impaired
function in those tissues. Fitting with this paradigm, we and
others have shown that human obesity is associated with ab-
normal accumulation of neutral lipids within skeletal myofibers
(Hulver et al., 2003; Malenfant et al., 2001), a phenomenon that
occurs in concert with reduced insulin stimulated glucose
transport (Dohm et al., 1988) and impaired insulin signal trans-
duction (Cortright et al., 2000; Goodyear et al., 1995; Itani et
al., 2000). Moreover, pharmacological and genetic manipula-
tions that deplete intramyocellular triacylglycerol (IMTG) have
been shown to concomitantly restore insulin sensitivity (Gavri-
lova et al., 2000; Kim et al., 2000; Schmitz-Peiffer et al., 1997;
Ye et al., 2001; Zierath et al., 1998). These reports add to aCELL METABOLISM : OCTOBER 2005 · VOL. 2 · COPYRIGHT © 2005 ELgrowing body of evidence that links genetic and/or acquired
defects in muscle lipid handling and IMTG accumulation to
whole-body energy dysregulation and glucose intolerance.
The underlying mechanisms that mediate obesity-associated
changes in muscle lipid metabolism are yet unknown, but
could provide novel therapeutic targets for the development of
antiobesity and/or antidiabetic drugs. In an effort to identify
candidate genes that might contribute to elevated IMTG con-
tent we performed transcriptional profiling analyses on skeletal
muscle from lean and obese humans using Affymetrix Gene-
Chip microarray technology. Herein, we report a unique upreg-
ulation of a lipogenic gene, stearoyl-CoA desaturase-1 (SCD1),
in skeletal muscle from obese humans. The SCD1 protein lo-
calizes to the endoplastic reticulum where it catalyzes the 9-
cis desaturation of saturated FA, preferring palmitoyl-CoA
(C16:0) and stearoyl-CoA (C18:0) as substrates and producing
palmitoleoyl-CoA (C16:1) and oleoyl-CoA (C18:1), respectively,
as products (Enoch et al., 1976; Ntambi, 1995). Oleoyl-CoA
and palmitoleoyl-CoA are essential substrates for the synthesis
of triacylglycerol (TAG), phospholipid (PL) and cholesterol es-
ters and represent two major fatty acids (FA) found in IMTG
(Enoch et al., 1976). In knockout mouse models, the absence
of SCD1 lowers tissues TAG content and protects against both
diet-induced and genetic forms of obesity (Cohen et al., 2002).
Thus, evidence from animal studies point to a principal role forSEVIER INC. DOI 10.1016/j.cmet.2005.09.002 251
A R T I C L ESCD1 in regulating tissue TAG levels as well as whole body
energy homeostasis (Miyazaki et al., 2001; Ntambi et al., 2002).
The present study now suggests that elevated expression of
SCD1 in skeletal muscle contributes to perturbations in lipid




The lean (BMI % 25 kg/m2) and obese (BMI R 35 kg/m2) sub-
jects that were studied in this investigation consisted of all fe-
males and were matched with respect to age and ethnicity
(Caucasian and African-American). The BMI cutoff for the
obese group was selected based on our previous report dem-
onstrating that muscle lipid accumulation is most severe in ex-
treme obesity (Hulver et al., 2003). In earlier studies we demon-
strated that this extremely obese/nondiabetic population
exhibits severe whole-body and muscle insulin resistance, as-
sessed by both biochemical and molecular markers (Caro et
al., 1989).
Skeletal muscle lipid accumulation
Figure 1A shows representative histological cross-sections of
rectus abdominus muscle obtained from lean and obese hu-
mans. Consistent with several previous reports (Goodpaster et
al., 2000; Malenfant et al., 2001), Oil Red O staining of neutral
lipids revealed more intramuscular lipid droplets in obese com-
pared to lean subjects. In a previous study we found that IMTG
accumulation in obese subjects was associated with a 43%
decrease in lipid oxidation (Hulver et al., 2003). Fatty acids en-
tering the muscle are primarily utilized by the competing path-
ways of β-oxidation and TAG synthesis. Figure 1B shows that
the amount of 14C-oleate incorporated in TAG, relative to the
amount oxidized, was greater in muscle strips from obese sub-
jects and correlated (r2 = 0.76, p < 0.01) with the BMI of the
donor subject.
Transcriptional profiling
Based on the results of our in vitro metabolic assays we sus-
pected that muscles from the obese subjects might be tran-
scriptionally programmed to promote lipid storage. In order to
test this hypothesis we performed DNA microarray analyses
using Affymetrix Human Genome chips U133A and U133B. To-
tal RNA from lean (n = 8, BMI, 23.8 ± 0.58) and obese (n = 8,
BMI, 53.8 ± 3.5) donors was extracted from a subset of the
muscle specimens that were used for the in vitro muscle strip
studies (Hulver et al., 2003). Table 1 shows relative mRNA ex-
pression levels of several candidate genes that could mediate
obesity-associated changes in muscle fuel partitioning (see
Supplemental Table 1 for normalized data). Surprisingly, mRNA
expression of the lipogenic transcription factor, sterol regula-
tory element binding protein 1c (SREBP1c), as well as putative
target genes involved in regulating glycerolipid synthesis; glyc-
erol-3-phosphate acyltransferase (GPAT) and diacylglycerol
acyltransferase (DGAT), were similar between the lean and
obese subjects. Expression of acetyl-CoA carboxylase (ACC)
β, an enzyme that acts as a negative regulator of mitochondrial
FA uptake and oxidation, was increased 29% in the obese sub-
jects. Genes encoding the lipid-activated transcription factors,
PPARs α and δ (p < 0.01) were slightly suppressed in obese252Figure 1. Abnormal lipid metabolism in muscle from obese subjects
A) Histological cross-sections of rectus abdominus muscles obtained from lean
and obese humans.
B) Fatty acid metabolism in muscle strips from lean (n = 8, BMI, 24.0 ± 0.79) and
obese (n = 11, BMI, 58.0 ± 4.02) humans. The partitioning of FA between oppos-
ing metabolic pathways was evaluated by dividing the rate (nmol/g wet weight/h) of
oleate esterified into TAG by the rate of oleate oxidized. Linear regression analy-
sis revealed a strong correlation (r2 = 0.76, p = 0.01) between FA partitioning and
body mass index of the donor subject.subjects, whereas PPARγ was elevated 57% (p < 0.05). PPAR-
targeted FA oxidative genes, including pyruvate dehydrog-
enase kinase 4 (PDK4), carnitine palmitoyltransferase 1β (CPT1β)
and malonyl-CoA decarboxylase (MCD) were either unaffected
or only marginally down-regulated by obesity.
Most remarkably however, obesity was associated with a ro-
bust (3-fold; p < 0.05) increase in transcript levels of SCD1,
which ranked highest amongst the known metabolic genes
that were differentially expressed between groups and repre-
sented the only lipid-related transcript that was regulated by
more than 2-fold in either direction (Table S2). Notably absent
from this list were adipocyte-enriched genes other than SCD1.
The Affymetrix array includes several classic adipocyte mark-
ers, including adipsin, adiponectin, AP2 and leptin, that were
equally low in muscle specimens obtained from obese com-
pared to lean subjects. This finding implies that adipose tissue
contamination was similarly low in both groups.
Expression profiling of a select set of candidate genes was
performed concurrently using real-time quantitative PCR and
muscle specimens obtained from an independent cohort of
subjects (Table 1). Consistent with results from the GeneChipCELL METABOLISM : OCTOBER 2005
Stearoyl-CoA desaturase 1 and human obesityTable 1. Transcriptional profiling of lipid-regulatory genes
GeneChip (obese versus lean) RTQ-PCR (obese versus lean)
Lipid biosynthesis genes
ACCα 0.82 ± .17
ACCβ 1.29 ± .09**
DGAT 1.04 ± 0.10 1.48 ± 0.26
GPAT 1.06 ± 0.02 1.38 ± 0.21
SCD1 3.86 ± 1.24* 3.13 ± 0.71*
SREBP1c 1.08 ± .13 1.00 ± .08
PPAR nuclear receptors
PPARα 0.86 ± 0.04 1.24 ± 0.10
PPARδ 0.62 ± 0.09* 1.17 ± 0.10
PPARγ 1.57 ± 0.23* 1.41 ± 0.20*
Fatty acid oxidative genes
CPT1β 0.97 ± 0.08 1.16 ± 0.20
MCD 0.81 ± 0.06** 1.28 ± 0.13
PDK4 0.89 ± 0.07 1.50 ± 0.20
Adipocyte-enriched genes
Adipose differentiation-related protein 1.08 ± 0.06
Fatty acid binding protein 4 (AP2) 1.12 ± 0.14
Adipsin 0.89 ± 0.11
Adipose most abundant gene transcript 1 1.02 ± 0.07
Total RNA was extracted from rectus abdominus muscles of obese (n = 8, BMI, 53.8 ± 3.5) and lean control subjects (n = 8, BMI, 23.8 ± 0.58) and transcriptional
profiling was performed on individual samples using Affymetrix Human Genome chips (column 1) as described in Experimental Procedures. Microarray results were
compared against results of RTQ-PCR analysis (column 2) using total RNA extracted from rectus abdominus muscles obtained from obese (n = 9, BMI, 51.1 ± 2.8)
and lean subjects (n = 7, BMI, 24.0 ± 0.58). Gene expression data are presented as fold-change (mean ± SEM) in obese relative to lean controls and were analyzed as
described in Experimental Procedures (*p < 0.05, **p < 0.01). ACC, acetyl CoA carboxylase; DGAT; diacylglycerol acyltransferase 1, GPAT; mitochondrial glycerol-3-
phosphate acyltransferase, SREBP1c; sterol regulatory element binding protein 1c, CPT1β; carnitine palmitoyltransferase 1β, MCD; malonyl-CoA decarboxylase, PDK4;
pyruvate dehydrogenase kinase 4, PPAR; peroxisome proliferator activated receptor.assay, as well as previous reports (Kruszynska et al., 1998;
Park et al., 1997), muscle expression of PPARγ was increased
in association with obesity. PPARs α and δ, along with several
FA oxidative target genes, were not differentially regulated be-
tween the two groups. Again, elevated muscle SCD1 mRNA
abundance (approximately 3-fold) emerged as a trait that cor-
responded with obesity, whereas expression of other lipogenic
genes was unremarkable. Thus, data from two independent
transcriptional profiling studies pointed to skeletal muscle
SCD1 as a strong genomic marker of obesity. The gene expres-
sion data were then correlated with results from our in vitro
metabolic studies. SCD1 mRNA levels exhibited a remarkably
strong positive association with BMI (r2 = 0.90, p < 0.001) (Fig-
ure S1) and rates of IMTG synthesis (r2 = 0.95, p < 0.001) (Fig-
ure 2A), and an equally impressive negative association with
rates of FA oxidation (r2 = 0.92, p < 0.001) (Figure 2B). Using
specimens from a separate cohort of subjects we found that
both BMI (r2 = 0.80, p < 0.001) and fasting insulin (r2 = 0.68,
p < 0.01) correlated positively with muscle SCD1 enzyme activ-
ity (Figures 2C and 2D). Accordingly, mean SCD1 enzyme ac-
tivity was 2.1-fold higher (p < 0.01) in muscle microsomes pre-
pared from obese compared to lean donors. Similar to our
previous reports, blood glucose values were not different
between groups (5.2 ± 0.2 versus 4.8 ± 0.3 mmol/liter in lean
and obese respectively), but fasting insulin levels were 5-fold
higher in obese compared to leans subjects, consistent with
insulin resistance.
Metabolic profiling
To determine whether increased SCD1 expression and activity
corresponded with changes in muscle FA composition, we pro-CELL METABOLISM : OCTOBER 2005ceeded to measure the FA desaturation index (C16:1/C16:0
and C18:1/C18:0) of muscle lipid extracts from lean (n = 7,
BMI, 23.6 ± 1.1 kg/m2) and obese (n = 7, BMI, 65.1 ± 7.4 kg/
m2) human subjects. The desaturation index of total tissue lip-
ids, 16:1/16:0 and 18:1/18:0 (Figures 3A and 3B), was 10%
and 40% (Figure 3B) greater in muscle samples from obese
compared to lean subjects, respectively. Likewise, the desatur-
ation index of free acyl-CoAs, 16:1/16:0 and 18:1/8:0 (Figures
3C and 3D), was 40% and 25% greater in muscles from obese
compared to lean subjects, respectively. The glycerolipid frac-
tion from muscle of obese subjects also contained a higher
percentage of C18:1 and lower percentages of both C18:0 and
C16:0 (Figure 3E). Similarly, when we evaluated the composi-
tion of muscle acylcarnitines, reflective of mitochondrial FA up-
take and metabolism (An et al., 2004), the oleoylcarnitine levels
(expressed as a percent of total long-chain acylcarnitines) were
increased from 15% in lean to 26% in the obese subjects (Fig-
ure 3F). Palmitoelyl carnitine esters (C16:1) were not detected.
In summary, elevated mRNA expression of SCD1, an enzyme
that catalyzes the synthesis of oleoyl-CoA, was indeed associ-
ated with increased C18:1 content of each of the lipid fractions
that were examined.
Human skeletal muscle cell culture
To address the possibility that obesity-associated perturba-
tions in lipid balance might reflect heritable and/or imprinted
metabolic defects, we next evaluated FA utilization in primary
human skeletal myocytes (HSKMC) that originated from lean
(n = 7, BMI = 23.5 ± 0.77) or obese (n = 9, BMI = 45.1 ± 3.89)
donors. Fatty acid oxidation was higher (p < 0.05) in myocytes253
A R T I C L EFigure 2. Relationship between muscle fatty acid
metabolism and SCD1 expression
Muscle samples were obtained from lean and obese
humans with a body mass index ranging from 22–
60 kg/m2. Gene expression data from Table 1 were
combined with results from in vitro metabolic as-
says (detailed in Hulver et al. [2003]) to show strong
correlations between SCD1 mRNA levels (A) rates
of intramuscular triacylglycerol (IMTG) synthesis and
(B) fatty acid oxidation. The relationships between
SCD1 activity and (C) body mass index and (D) se-
rum insulin levels were evaluated using rectus abdo-
minus specimens that were harvested from a sec-
ond cohort of subjects.into TAG by the rate of oleate oxidized, thereby providing an
Figure 3. Monounsaturated fatty acid content of
muscle lipids is increased with obesity
The desaturation index (16:1/16:0 and 18:1/18:0)
was measured in various muscle lipid fractions. To-
tal fatty acids (A) and (B) were extracted from rectus
abdominus skeletal muscle obtained from lean (n =
7, BMI, 23.6 ± 1.1 kg/m2) and obese (n = 7, BMI,
65.1 ± 7.4 kg/m2). Fatty acyl-CoAs (C) and (D) were
extracted from rectus abdominus muscle obtained
from lean (n = 8, BMI, 23.8 ± 0.58) and obese (n =
8, BMI, 53.8 ± 3.5). The FA composition of (E) intra-
myocellular glycerolipids and (F) mitochondrial-
derived acylcarnitines are expressed as a percent of
the total. Values represent the mean ± SEM, and
differences between groups were analyzed by Stu-
dent’s t test, *p < 0.05.
the Greenville, NC and Baton Rouge, LA geographic regions.from lean (1.99 ± 0.27 nmol/mg/hr) compared to obese (1.33 ±
0.15 nmol/mg/hr) subjects (Figure 4A). In contrast, FA incorpo-
ration into TAG was 83% greater (p < 0.02) in myocytes from
obese compared to lean subjects, whereas label incorporation
into PL was not different between groups (Figure 4B). Only
small amounts of FA (<10% of the total) were incorporated into
DAG and other minor lipid species (not shown). The partition-
ing of FA between opposing metabolic pathways was then
evaluated by dividing the rate (nmol/mg/hr) of oleate esterified254index of FA utilization. Obesity affected oxidation and esterifi-
cation in opposite directions, resulting in a 227% increase in
the TAG:oxidation partitioning index, from approximately 5:1 in
myocytes from lean subjects to 11:1 in those from obese sub-
jects. Linear regression analysis revealed a strong correlation
(r2 = 0.66, p < 0.001) between the FA partitioning index of pri-
mary myocytes and BMI of the donor subject (Figure 4C). No-
tably, the results presented in Figure 4 have been reproduced
using donors from multiple cohorts that were recruited fromCELL METABOLISM : OCTOBER 2005
Stearoyl-CoA desaturase 1 and human obesityFigure 4. Fatty acid metabolism and SCD1 expres-
sion in cultured HSKMC from lean and obese sub-
jects
Myoblasts were isolated from human rectus abdo-
minus muscle obtained from lean or obese subjects.
Day 8 myotubes were incubated 3 hr at 37°C in
DFM with 100 M [14C]oleate and 0.25% BSA.
A) Fatty acid oxidation was determined by measur-
ing 14C-label incorporation into CO2 and acid solu-
ble metabolites.
B) Glycerolipid synthesis was determined by mea-
suring 14C-label incorporation into triacylglycerol
(TAG) and phospholipid (PL).
C) Relationship between fatty acid partitioning
([14C]-oleate incorporation into TAG (nmol/mg pro-
tein/h) divided by the amount oxidized] and body
mass index of the donor subject. Metabolic assays
were performed in triplicate and values represent
the mean ± SEM from 7–9 subjects.
D) Total RNA was isolated and SCD1 mRNA expres-
sion was quantified by RTQ-PCR. Relative expres-
sion levels were normalized to 18S mRNA and data
are presented as means ± SEM of cells from 7 sub-
jects per group.
E) Cell extracts were prepared from day 8 myotubes
and used for Western blot analysis of SCD1 protein
abundance. Differences between groups were ana-
lyzed by Student’s t test. *p < 0.05, **p < 0.01.Because the expression profiling studies (Table 1) implicated
SCD1 as a potential mediator of aberrant muscle lipid metabo-
lism, we next sought to evaluate this same parameter in the
primary myocytes. SCD1 again emerged as a strong marker
of abnormal muscle lipid metabolism, as mRNA levels were
increased 2.8-fold (Figure 4D) and protein levels were in-
creased 5.7-fold (Figure 4E) in myotubes that originated from
obese compared to lean subjects. Predictably, SCD1 transcript
levels in muscle were approximately 10- to 20-fold lower than
those in adipose tissue (Table S3). However, the CT values for
SCD1 (obtained by RTQ-PCR) using muscle RNA were compa-
rable to other lipid-related metabolic transcripts, such as
CPT1β and MCD; suggesting that the gene is expressed at
moderately abundant levels in both muscle tissue and skeletal
myotubes. We also found that SCD1 mRNA levels were simi-
larly abundant in human fibroblasts, preconfluent myoblasts,
confluent myoblasts, and mature myotubes (Table S3); thus,
gene expression is not enriched in myoblasts and does not
appear to be regulated during myocyte differentiation. In con-
trast, SCD1 was expressed at low levels in human pre-adipo-
cytes and robustly induced upon adipocyte differentiation. This
finding is consistent with results from mouse 3T3-L1 adipo-
cytes (Ntambi et al., 1988) and indicates that contamination by
pre-adipocytes would not cause an artifactual increase in the
SCD1 mRNA levels measured in human myotubes.
To further address the possibility of adipocyte contamination
we carefully evaluated cellular morphology and performed
immunocytochemical staining of the cultures (Figure 5). Similar
to our previous report (Muoio et al., 2002b), we found that
80%–90% of HSKMC exhibited an elongated, multinucleated
morphology within 6–8 days after switching to differentiation
media. Formation of multinucleated myotubes and expression
of the hallmark muscle-specific protein, myosin, were similar
between cells from lean and obese donors (Figures 5A and 5B).CELL METABOLISM : OCTOBER 2005Consistent with the metabolic assays, Oil Red O staining of
neutral lipid droplets following an overnight FA exposure was
more intense in cells harvested from obese subjects. Impor-
tantly, lipid droplets were seen only in mature myotubes (Fig-
ures 5C–5F). Lipid-loaded adipocytes are characterized by
large triacylglycerol droplets that occupy the majority of the
cytoplasmic space. This distinct morphology was absent from
our cultures. Finally, the presence of SCD1 in mature myotubes
was confirmed by immunocytochemistry (Figure 5H). Western
blotting of cell and tissue lysates detected only a single 37 kDa
band representative of the SCD1 protein (data not shown), thus
demonstrating high specificity of the antibody. Immunostaining
of cultured myotubes from lean subjects revealed a diffuse sig-
nal that was co-expressed with sarcomeric myosin (Figure 5I),
again implying that the SCD1 detected in muscle tissue and/
or myotubes was not an artifact of adipocyte contamination.
Metabolic impact of SCD1 overexpression
To establish a causal relationship between SCD1 and lipid im-
balance, we proceeded to increase expression of the enzyme
in primary myocytes from lean subjects by transient transfec-
tion. We expected this maneuver to produce a metabolic phe-
notype resembling that displayed by myocytes from the obese
subjects. In preliminary experiments, we used a green fluores-
cent protein expression vector to confirm reasonably high effi-
ciency transfection (40%–50%) of primary human myotubes
(not shown). Likewise, using the hSCD1 expression vector we
were able to achieve a robust increase in SCD1 mRNA (>10-
fold, Figure 6A) with an approximate 2-fold increase in protein
when compared against control cells transfected with the
empty parent vector (Figure 6B). Transfected myotubes were
then subjected to acute (3 hr) incubations with radiolabeled
oleic acid to assess changes in FA metabolism. SCD1 overex-255
A R T I C L EFigure 5. Characterization of primary human myotubes
Differentiated HSKMC exhibit multi-nucleated (arrows) morphology that is characteristic of mature myotubes. Fluorescent photomicrographs (200×) show that immuno-
detection of the sarcomeric protein, myosin (green) was similar between cells from (A) lean and (B) obese subjects. Myotubes were incubated overnight with 500 M
fatty acid (oleate:palmitate 2:1) bound to 0.5% BSA and then fixed and stained for neutral lipids. Phase contrast photomicrographs (100×) revealed less intense staining
in myotubes that originated from (C) lean compared to (D) obese donors. (E) Higher magnification (200×) showing lipid droplets in mature myotubes. (F) Myotubes from
obese subjects that were incubated overnight with 0.5% BSA minus fatty acid displayed few lipid droplets. (G) Phase contrast photomicrographs (40×) of day 8
myotubes that were incubated with antibodies against human SCD1 and mouse sarcomeric myosin. Proteins were visualized using secondary antibodies conjugated
to distinct fluorophores. Fluorescent photomicrographs show co-expression of (H) SCD1 (red) and (I) sarcomeric myosin (green) in multinucleated myotubes. Negative
controls that were performed without addition of primary antibody did not present a fluorescent signal (data not shown).pression decreased oleate oxidation by 45% (Figure 6C) and
increased incorporation into myocellular TAG and PL by 22%
and 27%, respectively (Figure 6D). The net impact on cellular
lipid utilization was a 2.1-fold shift that favored the partitioning
of FA toward storage and away from oxidation.
Disruption of SCD1 in mice results in decreased hepatic ex-
pression and activity of ACCα and ACCβ (Dobrzyn et al.,
2004b), enzymes that promote lipogenesis and inhibit FA oxi-
dation. Both enzymes are inactivated via phosphorylation by
their upstream kinase, AMP-activated kinase (AMPK) (Dobrzyn
et al., 2004b). Interestingly, our microarray study indicated that
high muscle SCD1 expression in obese subjects was accom-
panied by an increase in ACCβ, the major isoform expressed256in muscle (Table 1). In light of the animal data, we reasoned that
the metabolic consequences of SCD1 overexpression might be
at least partly mediated by the induction and/or activation of
ACCβ. Indeed, transcript levels of ACCβ were increased 2.2-
fold in HSKMC transfected with hSCD1 compared to the
empty vector controls (Figure 6E). Additionally, SCD1 overex-
pression caused a decrease in the phosphorylated levels of
both AMPK and ACCβ (Figure 6F), which in turn favors in-
creased ACCβ activity and lower rates of FA oxidation (Mills et
al., 1983). Total protein levels of the AMPK α 1 and 2 catalytic
subuntis were unchanged whereas ACCβ protein expression
increased in alignment with changes in the transcript. In the
aggregate, these results demonstrate that high expression ofCELL METABOLISM : OCTOBER 2005
Stearoyl-CoA desaturase 1 and human obesityFigure 6. hSCD1 overexpression in primary HSKMC
alters FA partitioning
Preconfluent myoblasts were transiently transfected
with pcDNA3.0-hSCD1 or the empty parent vector.
After 7 days in DFM, cells were harvested to obtain
total RNA. Overexpression of SCD1 was confirmed
in differentiated myotubes by (A) semiquantitative
PCR of mRNA and (B) Western blot analysis of pro-
tein. β-actin mRNA and GAPDH protein were used
as loading controls. Metabolic assays were per-
formed following a 3 hr incubation with 100 M
[14C]oleate and 0.25% BSA. (C) Fatty acid oxidation
was determined by measuring 14C-label incorpora-
tion into CO2. (D) Glycerolipid synthesis was deter-
mined by measuring 14C-label incorporation into tri-
acylglycerol (TAG) and phospholipid (PL). All assays
were performed in triplicate and values represent
the mean ± SEM from four separate experiments.
Differences between groups were analyzed by Stu-
dent’s t test, *p < 0.05, **p < 0.01. (E) ACCβ mRNA
levels were quantified by RTQ-PCR and are ex-
pressed as relative units in cells transfected with
SCD1 versus empty vector controls. Cyclophilin B
was measured as an endogenous control. Data are
representative of five experiments and differences
between groups were analyzed by Student’s t test,
*p < 0.05. (F) Total and phosphorylated AMPK and
ACCβ were analyzed by immunoblotting with anti-
bodies against the AMPKα 1 and 2 catalytic sub-
units, ACCβ, AMPK-thr172, and ACCβ-ser79. GAPDH
protein expression was not different between
groups.SCD1 alters muscle lipid balance in a manner that is likely to
contribute to the development of obesity.
Discussion
Mounting evidence suggests that disordered muscle lipid me-
tabolism could play a central role in the development of obesity
and type 2 diabetes. Herein and in a previous report (Hulver
et al., 2003) we demonstrated that skeletal muscle strips from
extremely obese humans partition FA substrate preferentially
toward esterification pathways and away from mitochondrial
β-oxidation. Because these studies were performed using an
in vitro muscle system, the results imply that muscles from the
obese subjects are inherently programmed to store high levels
of IMTG. High IMTG are proposed to provide a surplus of en-
dogenous FA substrate that can be used to synthesize insulin
desensitizing lipid metabolites such as fatty acyl CoAs, diacyl-
glycerols, and ceramides. Whereas intense efforts have fo-
cused on identifying the precise lipid mediators that impair
insulin signaling, relatively few studies have addressed the un-
derlying mechanisms that cause IMTG to accumulate.
Using cDNA microarray analysis we discovered that obesity
was associated with a 3-fold increase in muscle mRNA levels
of the lipogenic enzyme, SCD1. In contrast, muscle expression
of other lipid biosynthetic and/or adipocyte-enriched genes
was similar between the lean and obese groups. SCD1 expres-
sion levels correlated strongly with BMI as well as the obesity-
related changes in muscle FA partitioning. Compelling evidence
from animal studies has implicated SCD1 as an important reg-
ulator of tissue lipid balance (Cohen et al., 2002; Dobrzyn etCELL METABOLISM : OCTOBER 2005al., 2004b). SCD1 catalyzes the synthesis of oleate and palmi-
toleate from saturated FA, and therefore plays a crucial role in
supplying the monounsaturated FA that are required for de
novo synthesis of TAG and PL (Enoch et al., 1976). Targeted
disruption of the SCD1 gene in knockout mice reduces TAG
levels and increases FA catabolism in liver (Ntambi and Miya-
zaki, 2004; Ntambi et al., 2002) and muscle (Dobrzyn et al.,
2004a). In comparison, we found that human muscle strips and
primary HSKMC that express high levels of SCD1 displayed
increased TAG synthesis and decreased FA oxidation.
Despite a convincing body of evidence that links defects in
muscle lipid metabolism to obesity and insulin resistance, it
remains uncertain whether these perturbations represent a
contributing factor or an adaptive consequence of the disease
process. In this regard, the HSKMC culture system provides
an attractive model in which muscle fuel metabolism can be
evaluated apart from the confounding systemic influences of
the obese environment. Similar to previous reports (Gaster et
al., 2004; Henry et al., 1995, 1996), we found that cultured
HSKMC express metabolic characteristics that approximate
the in vivo phenotype of the donor subject. Others have shown
that muscle cells from diabetes-prone Pima Indians exhibit im-
paired insulin responsiveness when compared against cells
from control subjects (Henry et al., 1996). Additionally, pertur-
bations in palmitate oxidation (Gaster et al., 2004) and insulin-
stimulated glycogen synthase activity (Nikoulina et al., 2002)
were evident in HSKMC obtained from a more heterogenous
pool of type 2 diabetics. We evaluated fuel metabolism in
HSKMC from lean compared to extremely obese (but nondia-
betic) subjects. In vivo assessments indicated that the obese
condition features abnormal accumulation of IMTG droplets257
A R T I C L Eand reduced FA catabolism. These same traits persisted in the
cultured myocytes that had been removed from the hyperinsu-
linemic, dyslipidemic in vivo environment for approximately 30
days. Moreover, HSKMC from obese compared to lean sub-
jects expressed 2.8-fold higher mRNA levels of SCD1, an out-
come nearly identical to that obtained using biopsied muscle
specimens.
We also demonstrated that specific overexpression of SCD1
in myotubes from lean subjects altered FA partitioning in a
manner that resembled the high rates of muscle TAG synthesis
and low rates of FA oxidation observed with obesity. Thus,
SCD1 overexpression in our cell system provoked metabolic
adjustments that were reciprocal to those displayed when the
gene was disrupted in knockout mice. Notably, the metabolic
impact of SCD1 overexpression was not limited to effects on
the acyl-CoA substrates of SCD1. Rather, elevated SCD1 activ-
ity caused robust changes in the metabolic fate of oleoyl-CoA,
the major monounsaturated product of the enzyme. This result
suggests that the alterations in FA partitioning were not simply
due to a mass action effect, but instead were conferred by a
more global level of regulation. The notion that changes in
SCD1 activity can impact multiple lipid-handling pathways is
also supported by results from the loss-of-function studies. In
liver and adipose tissue from SCD1 null mice, absence of the
gene not only decreases TAG synthesis (Miyazaki et al., 2000,
2001), but also increases metabolic rate and FA catabolism in
association with marked induction of several PPAR target
genes (Cohen et al., 2002; Ntambi et al., 2002). These observa-
tions imply that SCD1 might impart transcriptional control by
altering intracellular levels of lipid ligands that activate the
PPARs or other nuclear hormone receptors.
More recent investigations have shown that the SCD1 null
mice display enhanced AMPK activity, decreased expression
and activity of ACCα and ACCβ and lower levels of the ACC
product, malonyl-CoA (Dobrzyn et al., 2004a, 2004b). Similarly,
we found that overexpression of SCD1 in human myocytes re-
sulted in decreased phosphorylation of both AMPK and ACCβ,
and an approximate 2-fold induction of ACCβ mRNA and pro-
tein levels. Consistent with our cell-based studies, muscle
ACCβ mRNA expression was also up-regulated in the obese
subjects. Taken together with the animal data, our results sug-
gest that high SCD1 activity augments the production of malo-
nyl-CoA. Since malonyl-CoA functions as a potent inhibitor of
CPT1, the rate limiting enzyme of β-oxidation, changes in this
metabolite are likely to play an important role in conferring
SCD1-mediated changes in cellular lipid balance.
In addition to its impact on fuel metabolism, SCD1 also regu-
lates the FA composition of neutral lipids as well as membrane
PL (Enoch et al., 1976). Thus, SCD1-induced modifications in
lipid signaling molecules and/or membrane FA composition
might alter the activities of multiple regulatory enzymes and/or
proteins. The absence of SCD1 in knockout mice lowers the
oleate and palmityloleate content of various lipid fractions and
elevates palmitate and stearate levels (Ntambi et al., 2002). In
comparison, we found that high SCD1 activity in human mus-
cle corresponded with increases in the monounsaturated FA
composition of esterified lipids, free acyl-CoAs as well as mito-
chondrial-derived acylcarnitines. Others have suggested that
changes in the intracellular ratio of stearic to oleic acid may
impact skeletal muscle insulin sensitivity (Storlien et al., 1996).
Indeed, disruption of SCD1 appears to promote glucose toler-258ance in mice (Rahman et al., 2003). We found a positive corre-
lation between SCD1 activity and fasting insulin levels, but fur-
ther studies are required to determine whether or not SCD1
directly opposes insulin action in human muscle.
Results from our investigation prompt questions regarding
the mechanism(s) that drive muscle SCD1 induction in the set-
ting of obesity. Persistence of this feature in the cell culture
system implicates factors that may link to a genetic predisposi-
tion. However, because our study was executed with three rel-
atively heterogenous cohorts of subjects, the obesity-associ-
ated increases in SCD1 abundance are unlikely to stem from
a single inherited trait, but rather, might represent a common
manifestation of multiple susceptibility genes. Alternatively, ac-
quired defects in fuel metabolism may become imprinted into
the metabolic memory of myogenic satellite cells. Compelling
evidence from both animal and epidemiological studies indi-
cates that deviant nutrition occurring during critical develop-
mental periods can impose imprinted metabolic adaptations
that persist into adulthood (Waterland and Jirtle, 2004). These
observations suggest that transient environmental stresses can
trigger permanent alterations in metabolic control. The mecha-
nistic basis of “imprinting” is encompassed by the study of
epigenetics, a term referring to the stable propagation of gene
activity states that is not conferred by variations in DNA se-
quence (Egger et al., 2004). Thus, our findings could reflect an
epigenetic phenomenon in which obesity-induced changes in
DNA methylation and/or histone modification provoke irrevers-
ible perturbations in SCD1 gene regulation.
The SCD1 gene is transcriptionally regulated by many devel-
opmental, nutritional and hormonal factors (Ntambi, 1995). In
liver and adipose tissue, SCD1 gene expression is repressed
by leptin and induced by glucose and insulin (Ntambi and Miy-
azaki, 2004). Glucose oversupply has also been shown to in-
crease expression and activity of SCD1 in rat skeletal muscle
(Houdali et al., 2003). Both glucose and insulin-mediated stim-
ulation of SCD1 occurs through the action of the lipogenic tran-
scription factor, SREBP1c. Some studies also suggest that the
SCD1 gene might be controlled by the PPARs (Singh Ahuja et
al., 2001; Way et al., 2001). Whereas our transcriptional profil-
ing studies did not detect changes in SREBP1c, we did ob-
serve an obesity-associated increase in muscle mRNA levels
of PPARγ. Interestingly, in rodents, synthetic PPARγ ligands
have been shown to induce SCD1 gene expression in both liver
(Singh Ahuja et al., 2001) and skeletal muscle (Way et al.,
2001). The potential roles of these and other molecular path-
ways in regulating SCD1 expression in the HSKMC system
now awaits further investigation.
In summary, animal studies indicate that suppression of
SCD1 confers protection against obesity and insulin resis-
tance. Our studies now reveal a novel link between high muscle
SCD1 activity and severe obesity in humans. We propose that
elevated expression of SCD1 in skeletal muscle may represent
a core mechanism contributing to reduced FA oxidation, in-
creased IMTG synthesis and progression of the metabolic syn-
drome. The obese state is characterized by a constellation of
metabolic abnormalities, including hyperglycemia, hyperinsu-
linemia and leptin resistance, which may converge to augment
SCD1 expression. Pharmacological targeting of muscle SCD1
and/or its upstream regulators could provide new opportunitiesCELL METABOLISM : OCTOBER 2005




The lean (BMI % 25 kg/m2) and obese (BMI R 35 kg/m2) groups that were
studied in this investigation consisted of all females and were matched with
respect to age and ethnicity (Caucasian and African-American). Their medi-
cal charts were reviewed to ensure participants were not diabetic. Subjects
were excluded if fasting plasma glucose levels were >/= 6.9 pmole/L (126
mg/dL). The experimental protocol was approved by the Internal Review
Boards for Human Research at East Carolina University and the Pennington
Biomedical Research Center. Informed consent was obtained from all pa-
tients.
Lipid and immunostaining
Neutral lipid content was determined using the Oil Red O staining pro-
cedure, modified from Goodpaster et al. (Goodpaster et al., 2000) as pre-
viously described (Hulver et al., 2003). Staining of day 8 myotubes was
performed as described by (Muoio et al., 2002a). Myotubes were rinsed
three times with PBS, followed by fixing and permeablization in methanol
at −20°C for 20 min, and then incubated with the primary antibodies, mouse
anti-sarcomere myosin (MF20, Developmental Studies Hybridoma bank
University of Iowa, Iowa City, IA) and rabbit anti-Human SCD1(SCD11-A,
Alpha diagnostic Intl, Inc, San Antonio Texas), for 1 hr at room temperature.
Following a 3× wash in PBS plus 0.05% tween 20, cells were incubated for
1 hr at room temperature with secondary antibodies; goat anti-mouse IgG
conjugated to FITC (cat#115-095-166 Jackson Immuno Research Lab-
oratories, West Grove, PA) and goat anti-rabbit IgG (H+L) conjugated to
Alexa Fluor 594 (cat# A11012, Invitrogen Molecular probes, Carlsbad, CA)
for sarcomeric myosin and human SCD1, respectively. Proteins were visual-
ized by fluorescence microscopy using Nikon model eclipse TS 100 and
appropriate filters. Images were captured using the Metamorph software.
Negative controls that were performed without addition of primary antibody
did not present a fluorescent signal.
Lipid metabolism in intact skeletal muscle strips
Rectus abdominus muscle strips were harvested and incubated for 1 hr at
30°C in Krebs-Henseleit buffer with the addition of 0.75 Ci [1-14C]palmitate
(New England Nuclear, Boston, MA) and oxidation rates were determined
as previously described (Hulver et al., 2003). Neutral lipids were extracted
and quantified as previously described (Hulver et al., 2003).
Affymetrix microarray complementary RNA synthesis and labeling,
hybridization, and expression profiling
Total RNA was extracted from skeletal muscle samples using the TRIzol
reagent (Invitrogen Life Technologies) and RNeasy Mini kit (Qiagen). Double-
stranded cDNA was synthesized from 6 g of total RNA using the Super-
Script Choice system (Invitrogen) and the T7-Oligo(dT) promoter primer kit
(Affymetrix). cDNA was purified using Phase Lock Gels (Eppendorf 5-prime)
and used to synthesize biotin-labeled cRNA. Fifteen micrograms of biotin-
labeled cRNA was hybridized onto Human Genome U133A and U133B
GeneChips (Affymetrix). Procedures for cRNA preparation and GeneChip
processing were performed as previously described (Chen et al., 2002),
following quality control procedures that have been published (Hoffman et
al., 2004). A detailed description of all quality control parameters as well as
all image files (.dat) corresponding to this work is available http://microarray.
cnmcresearch.org.
Microarray data analysis
Data analysis was performed using Affymetrix Microarray Suite 5.0 software
to generate an absolute analysis for each chip. Each chip was scaled glob-
ally to a target intensity value of 800 to allow for inter-array comparisons.
All image files (.DAT) and cell intensity files (.CEL) corresponding to each
expression profile are available at http://microarray.cnmcresearch.org/
pgadatatable.asp. Further details of the analysis are provided in Supple-
mental Methods. Results of the microarray analysis were validated by per-
forming RTQ-PCR using rectus abdominus muscle specimens that wereCELL METABOLISM : OCTOBER 2005obtained from an independent cohort of obese (n = 9, BMI, 51.1 ± 2.8) and
lean (n = 7, BMI, 24.0 ± 0.58) subjects.
Real-time quantitative PCR
RTQ-PCR was performed using an ABI PRISM 7000 Sequence Detection
System instrument and TaqMan Universal PCR Master Mix used according
to manufactures specifications (Applied Biosystems, Inc., Foster City, CA).
Reactions were performed in triplicate and contained 20 ng cDNA as tem-
plate, 900 nM forward and reverse primers and 200 nM probe. Target gene
expression was normalized to 18S rRNA levels, which were assayed by
multiplexing with the manufactures 5#VIC-labeled, primer-limited 18S en-
dogenous control premix. Primers and 5# FAM-labeled Taqman probes were
purchased as pre-validated assays (ABI) or designed using Primer Express
software and sequences available in GenBank. Relative quantification of
target genes was calculated using the 2−CT method, which was validated
for each primer/probe set using a 6 point serial standard curve as described
previously (Muoio et al., 2002a). Derivation of the 2−CT equation has been
described in Applied Biosystems User Bulletin No. 2 (P/N 4303859).
Fatty acid analysis/SCD activity index
Total lipids were extracted from skeletal muscle obtained from lean (n = 7,
BMI, 23.6 ± 1.1 kg/m2) and obese (n = 7, BMI, 65.1 ± 7.4 kg/m2) human
subjects according to the methods of Bligh and Dryer (Bligh and Dryer,
1959). Fatty acids were methylated and analyzed by gas-liquid chromatog-
raphy as previously described (Barakat et al., 1976). Heptadecanoic acid
(Sigma, St. Louis, MO) was added as an internal standard for the quantita-
tion of FA. The FA species palmitate (16:0), palmitoleate (16:1), stearate
(18:0) and oleate (18:1) were identified by comparison of retention time with
authentic standards (Nu-Chek Prep, Inc, Elysian, MN). The desaturation in-
dex was determined by calculating product:substrate ratios (16:1/16:0 and
18:1/18:0) using the quantitated values for palmitoleate, palmitate, oleate
and stearate. Acylcarnitines were extracted from 50 mg rectus abdominus
muscle as previous described (An et al., 2004). Acylcarnitines were quanti-
fied by direct injection electrospray tandem mass spectrometry (Millington
et al., 1990), using a Quattro Micro LC-MS system (Waters-Micromass, Mil-
ford, MA) equipped with a model HTS-PAL autosampler (Leap Technol-
ogies, Carrboro, NC), a model 1100 HPLC solvent delivery system (Agilent
Technologies) and a data system running MassLynx software. Measurement
of fatty acyl CoAs was made as previously described (Hulver et al., 2003).
SCD1 activity
Microsomal preparations were made from rectus abdominus muscle sam-
ples from lean (n = 6, BMI, 23.3 ± 0.42) and obese (n = 7, BMI, 48.4 ± 3.23)
humans and SCD1 activity was measured as previously described (Miyazaki
et al., 2000). Serum insulin was measured in blood samples obtained from
these research participants as previously described (Hulver et al., 2002).
Cultures of primary human skeletal muscle cells
Rectus abdominus muscle samples weighing w50 mg were obtained from
lean (BMI = 23.5 ± 0.77, n = 7) and obese (BMI = 45.1 ± 3.89, n = 9)
subjects. Satellite cells were cultured and differentiated in multinucleated
myotubes as previously described (Muoio et al., 2002b). Fatty acid metabo-
lism assays were performed in triplicate as detailed in (Muoio et al., 2002b).
Construction of human SCD1 expression plasmids
The full coding region of human SCD1 (hSCD1) was generated by PCR
using human liver cDNA as the template and the following primers: 5#
primer, ttgaattcaccatgtacccatatgacgtcccggactacgccatgccggcccacttgctgc,
which contains a sequence of N-terminal hemagglutinin epitope (HA) tag
and a EcoRI restriction enzyme site; and 3# primer tgctcgagtcagccactcttg
tagtttcc, which contains a XhoI restriction enzyme site. The resulting PCR
product was cloned into pcDNA3 (Invitrogen, Carlsbad, CA) and designated
pcDNA3-HA-SCD1. The integrity of the PCR product was confirmed by
DNA sequencing.
Overexpression of SCD1 in HSKMC
Myoblasts were subcultured onto 6-well type I collagen-coated plates at a
density of w40 × 103 cells per well. Upon reaching w60% confluence,
myocytes were transiently transfected with either hSCD1 or empty vector
(pcDNA3.1) using GenePORTER transfection reagents (Gene therapy Sys-259
A R T I C L Etems, Inc, San Diego, CA) according to manufacturer’s specifications.
Twenty-four hours posttransfection, medium was replaced with growth me-
dium. When myocytes reached 90% confluence, growth media was re-
placed with differentiation media (DFM). Cell harvest and metabolic experi-
ments were performed on differentiation day 7.
SCD1 mRNA and protein overexpression was confirmed by semi-quanti-
tative PCR and Western blotting, respectively. cDNA was synthesized
(iScript cDNa kit, Bio-Rad, Hercules, Ca) from total RNA and amplified using
primer specific for hSCD1 (Forward: 5#-GCAGGACGATATCTCTAGCT-3#;
Reverse: 5#-GTCTCCAACTTATCTCCTCCATTC-3#) and β-actin (Forward:
5#-ACAGGATGCAGAAGGAGATTACT-3#; Reverse: 5#-TGATCCACATCTGC
TGGAAGGT-3#). PCR products were separated on a 2% agarose gel and
results of semiquantitative analysis were confirmed by RTQ-PCR. Western
analysis was performed using cell lysates harvested in 50 mM Hepes, (pH
7.5), 15 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 2 mM EDTA, 10% glycerol,
1% Triton x-100, 10 mM NaP2O7, 100 mM NaFl, 10 mM PMSF, and 10 g/
mL aprotinin. Proteins (30 g) were separated using a 10% Criterion-Tris-
HCl gel (Bio-Rad, Hercules, CA) and subsequently transferred to PVDF
membrane (Bio-Rad, Hercules, CA). Blots were probed with primary anti-
bodies against hSCD1 (4 g/mL, Alpha Diagnostics International, San Anto-
nio, TX) and GAPDH (1:100 dilution, Santa Cruz Biotechnology, Santa Cruz,
CA) followed by anti-rabbit and anti-goat secondary antibodies respectively
(1:8000 and 1:10000 dilutions, respectively; Santa Cruz Biotechnology,
Santa Cruz, CA). Proteins were visualized using Super-Signal Chemolu-
minescent Substrate (Pierce, Rockville, Il).
Supplemental data
Supplemental Data include Supplemental Experimental Procedures, Sup-
plemental References, three tables, and one figure and can be found with
this article online at http://www.cellmetabolism.org/cgi/content/full/2/4/251/
DC1/.
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